Home / Investor / Indian Drug Regulator Approves Wockhardt’s New Generation Oral Antibiotic Miqnaf® (Nafithromycin) for the Treatment of Community – Acquired Bacterial Pneumonia (CABP)
Indian Drug Regulator Approves Wockhardt’s New Generation Oral Antibiotic Miqnaf® (Nafithromycin) for the Treatment of Community – Acquired Bacterial Pneumonia (CABP)